Differential effects of the tumor necrosis factor alpha-blocker infliximab and etanercept on immunocompetent cells in vitro

International Immunopharmacology

Volumn 11, Issue 11, 2011, Pages 1724-1731

  Thaher, Firas ^a   Plankenhorn, Sandra ^a   Klein, Reinhild ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Etanercept; Immunomodulation; Infliximab; Peripheral blood mononuclear cells; TNF blocker

Indexed keywords

BCG VACCINE; CD56 ANTIGEN; CD69 ANTIGEN; ETANERCEPT; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INFLIXIMAB; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 5; INTERLEUKIN 6; LYMPHOTOXIN; TETANUS TOXOID; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ANTIGEN EXPRESSION; ARTICLE; CD8+ T LYMPHOCYTE; CELL CULTURE; CELL PROLIFERATION; CELL SUBPOPULATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DRUG MECHANISM; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOCOMPETENT CELL; IN VITRO STUDY; MACROPHAGE; MALE; MONOCYTE; NATURAL KILLER CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; TH1 CELL; TH2 CELL;

ADULT; ANTIBODIES, MONOCLONAL; CELL PROLIFERATION; CYTOKINES; CYTOTOXICITY, IMMUNOLOGIC; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOGLOBULIN G; MACROPHAGES; MALE; NATURAL KILLER T-CELLS; RECEPTORS, TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 80054987092     PISSN: 15675769     EISSN: 18781705     Source Type: Journal    
DOI: 10.1016/j.intimp.2011.06.005     Document Type: Article

References (63)

1. C. Popa, M.G. Netea, P.L.C.M. van Riel, J.W.M. van der Meer, and A.F.H. Stalenhoef The role of TNF-α in chronic inflammatory conditions, intermediary metabolism, and cardiovascular risk J Lipid Res 48 2007 751 762
2. D. Tracey, L. Klareskog, E.H. Sasso, J.G. Salfeld, and P.P. Tak Tumor necrosis factor antagonist mechanisms of action: a comprehensive review Pharmacol Ther 117 2008 244 279
3. C.A. Dinarello Differences between anti-tumor necrosis factor-a monoclonal antibodies and soluble TNF receptors in host defense impairment J Rheumatol 32 2005 40 47 (Pubitemid 40365780)
4. K. Reinhart, and W. Karzai Anti-tumor necrosis factor therapy in sepsis: update on clinical trials and lessons learned Crit Care Med 29 Suppl. 7 2001 121 125
5. M. Feldmann, and R.N. Maini Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned? Annu Rev Immunol 19 2001 163 196 (Pubitemid 32368033)
6. W. Lew, A.M. Bowcock, and J.G. Krueger Psoriasis vulgaris: cutaneous lymphoid tissue supports T-cell activation and 'Type 1' inflammatory gene expression Trends Immunol 25 2004 295 305 (Pubitemid 38610353)
7. X. Valencia, G. Stephens, R. Goldbach-Mansky, M. Wilson, E.M. Shevach, and P.E. Lipsky TNF downmodulates the function of human CD4 + CD25hi T-regulatory cells Blood 108 2006 253 261 (Pubitemid 43990636)
8. M.R. Ehrenstein, J.G. Evans, A. Singh, S. Moore, G. Warnes, and D.A. Isenberg Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNFα therapy J Exp Med 200 2004 277 285 (Pubitemid 39031247)
9. H. Tilg, A. Moschen, and A. Kaser Mode of function of biological anti-TNF agents in the treatment of inflammatory bowel diseases Expert Opin Biol Ther 7 2007 1051 1059 (Pubitemid 47204358)
10. A.S. Haider, J. Cohen, J. Fei, L.C. Zaba, I. Cardinale, and K. Toyoko Insights into gene modulation by therapeutic TNF and IFNg antibodies: TNF regulates IFNg production by T cells and TNF-regulated genes linked to psoriasis transcriptome J Invest Dermatol 128 2008 655 666 (Pubitemid 351252666)
11. F. Moriconi, D. Raddatz, N.A.H. Ho, S. Yeruva, J. Didas, and G. Ramadori Quantitative gene expression of cytokines in peripheral blood leukocytes stimulated in vitro: modulation by the anti-tumor necrosis factor-alpha antibody infliximab and comparison with the mucosal cytokine expression in patients with ulcerative colitis Transl Res 150 2007 223 232 (Pubitemid 47444612)
12. B. Scallon, A. Cai, N. Solowski, A. Rosenberg, X.-Y. Song, and D. Shealy Binding and functional comparisons of two types of tumor necrosis factor antagonists J Pharmacol Exp Ther 301 2002 418 426 (Pubitemid 34429950)
13. J.M. van den Brande, H. Bratt, and G.R. van den Brink Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease Gastroenterology 124 2003 1774 1784
14. W.J. Sandborn, S.B. Hanauer, S. Katz, M. Sadi, D.G. Wolf, and R.D. Baerg Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial Gastroenterology 121 2001 1088 1094 (Pubitemid 33022088)
15. A.B. Gottlieb Psoriasis: emerging therapeutic strategies Nat Rev Drug Discov 4 2005 19 34 (Pubitemid 40109587)
16. S. Tsiodras, G. Samonis, D.T. Boumpas, and D.P. Kontoyiannis Fungal infections complicating tumor necrosis factor α blockade therapy Mayo Clin Proc 83 2008 181 194 (Pubitemid 351303102)
17. R.S. Wallis, and S. Ehlers Tumor necrosis factor and granuloma biology: explaining the differential infection risk of etanercept and infliximab Semin Arthritis Rheum 34 Suppl. 1 2005 34 38
18. P. Caramaschi, L.M. Bambara, S. Pieropan, I. Tinazzi, A. Volpe, and D. Biasi Anti-TNFalpha blockers, autoantibodies and autoimmune diseases Joint Bone Spine 76 2009 333 342
19. W.F. Rigby Drug insight: different mechanisms of action of tumor necrosis factor antagonists-passive-aggressive behavior? Nat Clin Pract Rheumatol 3 2007 227 233 (Pubitemid 46860407)
20. C.S. Via, A. Shustov, V. Rus, T. Lang, P. Nguyen, and F.D. Finkelman In vivo neutralization of TNFalpha promotes humoral autoimmunity by preventing the induction of CTL J Immunol 167 2001 6821 6826 (Pubitemid 33144173)
21. Z. Kaymakcalan, P. Sakorafas, S. Bose, S. Scesney, L. Xiong, and D.K. Hanzatian Comparisons of affinities, avidities, and complement activation of adalimumab, infliximab, and etanercept in binding to soluble and membrane tumor necrosis factor Clin Immunol 131 2009 308 316
22. T. Arora, R. Padaki, L. Liu, A.E. Hamburger, A.R. Ellison, and S.R. Stevens Differences in binding and effector functions between classes of TNF antagonists Cytokine 45 2009 124 131
23. H. Mitoma, T. Horiuchi, H. Tsukamoto, Y. Tamimoto, Y. Kimoto, and A. Uchino Mechanisms for cytotoxic effects of anti-tumor necrosis factor agents on transmembrane tumor necrosis factor alpha-expressing cells: comparison among infliximab, etanercept, and adalimumab Arthritis Rheum 58 2008 1257
24. H. Barth, P.A. Berg, and R. Klein Methods for the in vitro determination of an individual disposition towards TH1- or TH2-reactivity by the application of appropriate stimulatory antigens Clin Exp Immunol 134 2003 78 85 (Pubitemid 37186591)
25. A. Kivling, L. Nilsson, and M. Faresjö How and when to pick up the best signals from markers associated with T-regulatory cells? J Immunol Methods 345 2009 29 39
26. H. Barth, K. Klein, A. Börtlein, A. Guseo, P.A. Berg, and H. Wiethölter Analysis of immunoregulatory T-helper cell subsets in patients with multiple sclerosis: relapsing-progressive course correlates with enhanced Th1, relapsing-remitting course with enhanced TH0 reactivity J Neuroimmunol 133 2002 175 183 (Pubitemid 35346739)
27. R. Klein, M. Schwenk, R. Heinrich-Ramm, and D.M. Templeton Diagnostic relevance of the lymphocyte transformation test for sensitization to beryllium and other metals Pure Appl Chem 76 2004 1269 1281
28. R. Klein, M. Schwenk, and D.M. Templeton Cytokine profiles in human exposure to metals (IUPAC Technical Report) Pure Appl Chem 78 2006 2155 2168
29. R. Klein, S. Buck, K. Claßen, M. Rostock, and R. Huber Enhanced in vitro activation of immunocompetent cells in healthy individuals being subcutaneously 'vaccinated' with placebo (physiological saline) Clin Immunol 126 2008 322 331 (Pubitemid 351221428)
30. R. Klein Evidence for immunological (allergic) mechanisms in a subgroup of patients with phenprocoumon-induced liver disease Eur J Clin Pharmacol 65 2009 1195 1201
31. N.W. Brattig, G.J. Diao, and P.A. Berg The specificity of the lymphocyte transformation test in a patient with hypersensitivity reactions to pyrazolone compounds. A 10-week follow-up study before and after rechallence Eur J Clin Pharmacol 35 1988 39 45
32. B. Elewski, C. Leonardi, A.B. Gottlieb, B.E. Strober, M.A. Simiens, and M. Dunn Comparison of clinical and pharmacokinetic profiles of etanercept 25 mg twice weekly and 50 mg once weekly in patients with psoriasis Br J Dermatol 156 2007 138 142 (Pubitemid 44924157)
33. A.A. Fasanmade, O.J. Adedokun, J. Ford, D. Hernandez, J. Johanns, and C. Hu Population pharmacokinetic analysis of infliximab in patients with ulcerative colitis Eur J Clin Pharmacol 2009 2009 1211 1228
34. I. Nestorov Clinical pharmacokinetics of TNF antagonists: how do they differ? Semin Arthritis Rheum 34 Suppl. 1 2005 12 18
35. I. Nestorov, R. Zitnik, T. DeVries, A.M. Nakanishi, A. Wang, and C. Banfield Pharmacokinetics of subcutaneously administered etanercept in subjects with psoriasis Br J Clin Pharmacol 64 2006 435 445 (Pubitemid 44401526)
36. J.T. Sullivan, L. Ni, C. Sheelo, M. Salfi, and P.M. Peloso Bioequivalence of liquid and reconstituted lyophilized etanercept subcutaneous injections J Clin Pharmacol 46 2006 654 661
37. M.L.V. Watkins, P.L. Semple, B. Abel, W.A. Hanekom, G. Kaplan, and S.R. Ress Exposure of cord blood to Mycobacterium bovis BCG induces an innate response but not a T-cell cytokine response Clin Vaccine Immunol 15 2008 1666 1673
38. H. Appel, R. Scheer, H. Haibel, P. Wu, I. Spiller, and H. Brandt In vitro observations of T cell responsiveness to recall antigens during tumor necrosis factor-α-blocking therapy in patients with ankylosing spondylitis J Rheumatol 34 2007 2264 2270 (Pubitemid 350076889)
39. J. Keane, S. Gershon, R.P. Wise, E. Mirabile-Levens, J. Kasznica, and WDeal Schwieterman Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent N Engl J Med 345 2001 1098 1104
40. N. Charles, D. Hardwick, E. Daugas, G.G. Illei, and J. Rivera Basophils and the T helper 2 environment can promote the development of lupus nephritis Nat Med 16 2010 701 707
41. M. Aringer, and J.S. Smolen TNF inhibition in SLE: where do we stand? Lupus 18 2009 5 8
42. F. Coury, C. Ferraro-Peyret, S. Le Cam, S. Guerin, J. Tebib, and J. Sibilia Peripheral blood lymphocytes from patients with rheumatoid arthritis are differentially sensitive to apoptosis induced by anti-tumor necrosis factor-alpha therapy Clin Exp Rheumatol 26 2008 234 239 (Pubitemid 351659129)
43. W. Hueber, B.H. Tomooka, F. Batliwalla, W. Li, P.A. Monach, and R.J. Tibshirani Blood autoantibody and cytokine profiles predict response to anti-tumor necrosis factor therapy in rheumatoid arthritis Arthritis Res Ther 11 2009 R76 10.1186/ar2706
44. T. Kishimoto IL-6: from its discovery to clinical applications Int Immunol 22 2010 347 352
45. H. Mitoma, T. Horiuchi, N. Hatta, H. Tsukamoto, S.-I. Harashima, and Y. Kikuchi Infliximab induces potent anti-inflammatory responses by outside-to-inside signals through transmembrane TNF-α Gastroenterology 128 2005 376 392 (Pubitemid 40431090)
46. C.L. Maynard, and C.T. Weaver Diversity in the contribution of interleukin-10 to T-cell-mediated immune regulation Immunol Rev 226 2008 219 233
47. M. Feuerer, J.A. Hill, D. Mathis, and C. Benoist Foxp3+ regulatory T cells: differentiation, specification, subphenotypes Nat Immunol 10 2009 689 695
48. J. Bayry, S. Sibéril, F. Triebel, D.F. Tough, and S.V. Kaveri Rescuing CD4 + CD25+ regulatory T-cell functions in rheumatoid arthritis by cytokine-targeted monoclonal antibody therapy Drug Discov Today 12 2007 548 552 (Pubitemid 47039302)
49. S. Nadkarni, C. Mauri, and M.R. Ehrenstein Anti-TNF-α therapy induces a distinct regulatory T cell population in patients with rheumatoid arthritis via TGF-β J Exp Med 204 2007 33 39 (Pubitemid 46148753)
50. K. Asadullah, W. Sterry, K. Stephanek, D. Jasulaitis, M. Leupold, and H. Audring IL-10 is a key cytokine in psoriasis. Proof of principle by IL-10 therapy: a new therapeutic approach J Clin Invest 101 1998 783 794 (Pubitemid 28096075)
51. D.R. Littman, and A.Y. Rudensky Th17 and regulatory T cells in mediating and restraining inflammation Cell 140 2010 845 858
52. J. Sieper, and J.M. van den Brande Diverse effects of infliximab and etanercept on T lymphocytes Semin Arthritis Rheum 34 Suppl. 1 2005 23 27
53. A. Nesbitt, G. Fossati, M. Bergin, P. Stephens, S. Stephens, and R. Foulkes Mechanism of action of Certolizumab Pegol (CDP870): in vitro comparison with other anti-tumor necrosis factor α agents Inflamm Bowel Dis 13 2007 1323 1332 (Pubitemid 350206841)
54. C. Antoni, and J. Braun Side effects of anti-TNF therapy: current knowledge Clin Exp Rheumatol 20 2002 S152 S157
55. J. Zou, M. Rudwaleit, J. Brandt, A. Thiel, J. Braun, and J. Sieper Up regulation of the production of tumour necrosis factor alpha and interferon gamma by T cells in ankylosing spondylitis during treatment with etanercept Ann Rheum Dis 62 2003 561 564 (Pubitemid 36606291)
56. N.M. Moutsopoulos, G.E. Katsifis, N. Angeloy, R.A. Leakan, V. Sankar, and S. Pillemer Lack of efficacy of etanercept in Sjögren syndrome correlates with failed suppression of tumor necrosis factor alpha and systemic immune activation Ann Rheum Dis 67 2008 1437 1443
57. H. Bruns, C. Meinken, P. Schauenberg, G. Härter, P. Kern, and R.L. Modlin Anti-TNF immunotherapy reduces CD8+ T cell-mediated antimicrobial activity against Mycobacterium tuberculosis in humans J Clin Invest 119 2009 1167 1177
58. T. Werfel, M. Boeker, and A. Kapp Rapid expression of the CD69 antigen on T cells and natural killer cells upon antigenic stimulation of peripheral blood mononuclear cell suspension Allergy 52 1997 465 469 (Pubitemid 27244164)
59. negative phenotype Rheumatology 42 2003 870 878 (Pubitemid 37220937)
60. C. Ottaviani, F. Nasorri, C. Bedini, O. de Pita, G. Girolomi, and A. Cavani CD56brightCD16(-) NK cells accumulate in psoriatic skin in response to CXCL 10 and CCL5 and exacerbate skin inflammation Eur J Immunol 36 2006 118 128 (Pubitemid 43116398)
61. G. Caron, Y. Delneste, J.P. Aubry, G. Magistrelli, N. Herbault, and A. Blaecke Human NK cells constitutively express membrane TNF-alpha (mTNFalpha) and present mTNFalpha dependent cytotoxic activity Eur J Immunol 29 1999 3588 3595 (Pubitemid 29527806)
62. J.H. Kempen, E. Daniel, J.P. Dunn, C.S. Foster, S. Gangaputra, and A. Hanish Overall and cancer related mortality among patients with ocular inflammation treated with immunosuppressive drugs: retrospective cohort study BMJ 339 2009 10.1136/bmj.b2480
63. F.B. Pallavicini, R. Caporali, P. Sarzi-Puttini, F. Atzeni, C. Bazzani, and R. Goria Tumour necrosis factor antagonist therapy and cancer development: analysis of the LORHEN registry Autoimmun Rev 9 2010 175 180